



Bal Pharma Limited

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

19/11/2018

BSE Limited
Mumbai.

Dear Sir,

Ref : Compliance with Regulation 47 of SEBI (LODR) Regulations , 2015.

With reference to the above, we are submitting to the exchange news paper publications of Un audited financial results of the Company for the quarter and half year ended 30/09/2018 published in Financial Express (English) and Sanjay vani (vernacular), on 16th November 2018.

Please take the same on record.

Thanking You.

For Bal Pharma Ltd

Authorised Signatory.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820



(http://epaper.sanjeva

(http://epape



BAL PHARMA LIMITED

CIN:L85110KA1987PLC008368

Regd Office: 21&22, Bommasandra Industrial Complex, Bangalore-99.

Phone: 41379500, Fax: 22354057, email: investor@balpharma.com.

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2018

Sl. No.	Particulars	Quarter ended 30.09.2018 Un-audited	Quarter ended 30.09.2017 Un-audited	Half year ended 30.09.2018 Un-audited	Half year ended 30.09.2017 Un-audited
1	Total income from operations.	5841.43	5555.13	11191.57	10176.19
2	Net Profit/(Loss) for the period (Before Tax, Exceptional items and/or Extraordinary items)	116.17	233.22	341.38	358.51
3	Net Profit/(Loss) for the period before tax (After exceptional and/or extraordinary items)	116.17	233.22	341.38	358.51
4	Net profit/(Loss) for the period after tax	46.24	154.23	279.75	273.01
5	Total comprehensive income for the period	46.24	154.23	279.75	247.24
6	Equity share capital	1417.24	1417.24	1417.24	1417.24
7	Reserves	-	-	-	-
8	Earnings per share of ₹10 each for continuing and discontinuing activities.				
	Basic	0.33	1.09	1.97	1.74
	Diluted	0.33	1.09	1.97	1.74

Note: The above is an extract of the detailed format of financial results filed with stock exchanges under Regulation 33 of SEBI (LODR) Regulations, 2015. The unabridged version of the standalone financial results are available on the website of the stock exchanges and also on our website i.e www.balpharma.com.

Date : 14-11-2018
Place: Bangalore

By the order of the Board of Directors
For Bal Pharma Limited
Sd/- Shailesh Siroya
Managing Director

New Fund Offer

SUNDARAM Equity Savings Fund

An open ended scheme investing in equity, arbitrage and debt.

NFO Period
Nov 16th 2018 - Nov 30th 2018

Scheme reopens for ongoing subscription/redemption from 14th Dec 2018.

1	Net Assets at the end of the period	68.40	47.79	116.19
2	Net Assets at the beginning of the period	40.44	37.51	77.95
3	Net Assets at the end of the period (after deducting the amount of the NFO)	68.40	37.51	116.19
4	Net Assets at the beginning of the period (after deducting the amount of the NFO)	40.44	37.51	77.95
5	Net Assets at the end of the period (after deducting the amount of the NFO)	68.40	37.51	116.19
6	Net Assets at the beginning of the period (after deducting the amount of the NFO)	40.44	37.51	77.95
7	Net Assets at the end of the period (after deducting the amount of the NFO)	68.40	37.51	116.19
8	Net Assets at the beginning of the period (after deducting the amount of the NFO)	40.44	37.51	77.95
9	Net Assets at the end of the period (after deducting the amount of the NFO)	68.40	37.51	116.19
10	Net Assets at the beginning of the period (after deducting the amount of the NFO)	40.44	37.51	77.95



DYNAMATIC TECHNOLOGIES LIMITED

CIN: L22000KA1987PLC008368

Regd. Office: Dynamatic Park, Bommasandra Industrial Complex, Bangalore-99.

Phone: 41379500, Fax: 22354057, email: investor@balpharma.com.

Particulars	30.09.2018 Un-audited	30.09.2017 Un-audited	30.09.2018 Un-audited	30.09.2017 Un-audited
Continuing operations	14,400	77,100	22,200	14,400
Discontinued operations	-	-	-	-
Total	14,400	77,100	22,200	14,400

₹10K SIP for 5 Yrs
can become
₹17L

Invest in Top Mutual Funds 2018




START SIP

UPWARDLY.

(<http://epaper.financialexpress.com/>)







WWW.FINANCIAREXPRESS.COM

FINANCIAL EXPRESS

FRIDAY, NOVEMBER 16, 2018

 BAL PHARMA LIMITED CIN: L85110KA:1987PLC008363 Regd. Office: 21,622, Barmasandra industrial complex, Bangalore-99. Phone: 41379500. Fax: 22354057. email: investor@balpharma.com.					
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2018					
Sl. No.	Particulars	Quarter ended 30.09.2017	Quarter ended 30.09.2017	Half year ended 30.09.2017	Half year ended 30.09.2017
		Un-audited	Un-audited	Un-audited	Un-audited
1	Total income from operations.	5941.43	5595.13	11191.57	10716.19
2	Net Profit/(Loss) for the period (Before Tax, Exceptions Items and/or Extraordinary Items)	118.17	233.22	241.38	358.51
3	Net Profit/(Loss) for the period before tax [After exceptional and/or extraordinary items]	118.17	233.22	241.38	358.51
4	Net profit/(Loss) for the period after tax	40.24	154.23	279.75	273.01
5	Total comprehensive income for the period	46.24	154.23	279.75	247.24
6	Equity share capital	1417.24	1417.24	1417.24	1417.24
7	Reserves	-	-	-	-
8	Earnings per share of ₹10 each for continuing and discontinuing activities.				
	Basic	0.33	1.08	1.57	1.74
	Diluted	0.33	1.08	1.57	1.74

Note: The above is an extract of the detailed format of financial results filed with stock exchanges under Regulation 32 of SEBI (LODR) Regulations, 2015. The unabridged version of the standalone financial results are available on the website of the stock exchanges and also on our website www.balpharma.com.

By order of the Board of Directors,
 For Bal Pharma Limited
 Sd/- Shankesh Sinha
 Managing Director

Date: 14-11-2018
 Place: Bangalore

		THAKRAL SERVICES (INDIA) LIMITED			
		CIN - L70101KA1983PLC005140, Regd. Office: 6th Floor, The Estate, 121, Dickenson Road, Bangalore - 560042. Ph: 080-25593891, Fax: 25593739			
		website: www.thakral-india.co.in, e-mail: tsll@thakral-india.co.in			
		EXTRACT OF STATEMENT OF (UN-AUDITED) FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2018			
Sl. No.	Particulars	Rs. in Lakhs (Rounded off to nearest integer)			
		30-09-2018	30-09-2017	30-09-2018	31-03-2018
		Un-audited	Un-audited	Un-audited	Audited
1	Total Income from Operations	541.48	470.47	980.44	2017.25
2	Net Profit/(Loss) for the period before Tax, Exceptional and/or Extraordinary Items	(23.40)	(28.48)	(64.24)	(51.72)
3	Net Profit/(Loss) for the period before tax(after Exceptional and/or Extraordinary items)	(23.40)	(28.48)	(64.24)	(51.72)
4	Net Profit/(Loss) for the period after tax(after Extraordinary and/or Extraordinary Items)	(13.82)	(148.74)	(32.46)	(103.87)
5	Net Comprehensive Income for the period (Comprising Profit/(Loss) for the period after tax and Other Comprehensive Income (after tax)	(13.82)	(148.74)	(32.46)	(116.13)
6	Equity Share Capital (Face value of Rs.1/- each)	362.05	362.05	362.05	362.05
7	Reserves (excluding Retention Reserve) as shown in the Audited Balance Sheet of the previous year	0	0	0	0
8	Earning a Per Share (of Rs.2/- each) (for continuing and discontinued operations) - Basic & Diluted	(0.77)	(0.47)	(0.75)	(0.54)

Notes: - 1) The above is an extract of the aforesaid financial results for the quarter and half year ended 30.09.2018 filed with the Stock Exchange pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the financials is available on the Stock Exchange website www.bseindia.co.in and on the company website www.thakral-india.co.in.

2) The above results, reviewed by the Audit Committee, have been approved by the Board of Directors at its meeting held on 14.11.2018.

For Thakral Services (India) Limited
Sd/-

Ramesh Chandra Shrivastava,
Managing Director (DIN No. 00237363)

Date: 14.11.2018
Place: Bangalore

[illegible]

IN THE COURT OF THE PRINCIPAL
SUBORDINATE JUDGE OF
CEDEXATOUR
P.R.O.P. No. 86/2017
F. Repettoles Perumio ... Prictine
...
2. S. Sargam Annamalai S. K. Jayaram
S. K. Thomas, a. S. J. Richard
S. K. K. Monro, a. S. J. Premalatha
S. S. J. Sanyal, a. S. J. K. Ramaswami
No. 222, 2nd Main Road,
4th Cross, K.G. 14th
Vinoth Nagar, Bangalore - 560 045.
Karnataka State. ... Repettoles

GENERAL NOTICE

Take notice that the above petition
has been filed P.R.C.P. No. 36/2017 to probate
the will of 23-01-1990 executed by
P.S.K. Jod at Cornbarore and the same
posted to 20.11.2018 for your appearance
You are hereby directed to appear on the
date fixed in person or through an Advocate
to offer your objection if any on that date

[illegible]

CEETA INDUSTRIES LIMITED

(CIN: L25110KA1984PL0021404)

REGD. OFFICE : PLOT NO.24-3R, KADABE INDUSTRIAL AREA, SATYANARAYANA GOLA, TALUKURU - 572 104,
KARNATAKA, PIN- 616-2212630 Email - info@ceeta.com, Website - www.ceeta.com

(Rs. - in Lakhs)

EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2018

Sl. No.	Particulars	Quarter ended 30.09.2018	Quarter ended 30.09.2017	Half year ended 30.09.2018	Year ended 31.03.2018
		Un-audited	Un-audited	Un-audited	Audited

1	Total Income from operations (Net)	430.40	58.42	844.61	530.04
---	------------------------------------	--------	-------	--------	--------